VYNE THERAPEUTICS INC (VYNE) Stock Income Statement
NASDAQ:VYNE - US92941V3087 - Common Stock
0.334 USD
+0.01 (+3.47%)
0.335 USD
+0 (+0.3%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 476.00K | 501.00K | 424.00K | 480.00K | 930.00K | |||
| Cost Of Goods | N/A | N/A | N/A | N/A | 3.35M | |||
| Gross Profit | N/A | N/A | N/A | N/A | 11.41M | |||
| Operating Expenses | 43.08M | 44.14M | 29.68M | 34.77M | 39.84M | |||
| Research and Development | 30.94M | 30.95M | 16.31M | 18.39M | 19.54M | |||
| Selling, General, and Administrative Expenses | 12.13M | 13.19M | 13.38M | 16.39M | 20.30M | |||
| Operating Income | -42.60M | -43.64M | -29.26M | -34.30M | -38.91M | |||
| Interest Income/Expense | N/A | N/A | N/A | 0.00 | -5.61M | |||
| Other Income/Expense | 4.08M | 3.83M | 1.39M | 360.00K | -140.00K | |||
| Income Before Taxes | -38.52M | -39.80M | -27.87M | -33.93M | -44.66M | |||
| Income Tax | N/A | 4.00K | 0.00 | 10.00K | -450.00K | |||
| Net Income | -38.55M | -39.83M | -28.45M | -23.21M | -73.33M | |||
| EBITDA | N/A | -43.63M | N/A | -34.23M | -38.80M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.90 | -0.93 | -2.76 | -7.27 | -25.63 | |||
| Non GAAP EPS | -0.90 | -0.94 | -7.04 | -11.07 | -16.75 | |||
| Statistics | ||||||||
| Gross Profit Margin | N/A | N/A | N/A | N/A | 1226.56% | |||
| Profit Margin | -8097.69% | -7950.90% | -6710.38% | -4835.42% | -7884.95% | |||
| Operating Profit Margin | -8949.58% | -8709.98% | -6900.47% | -7145.83% | -4183.87% | |||
All data in USD